In an animal study on this subject, it was shown that finerenone added to standard treatment provided significant benefits in creatinine, interleukin-6, urinary neutrophil gelatinase-associated lipocalin, and blood pressure levels in a tacrolimus-mediated renal failure model compared to the group not receiving the drug [40]. This evidence concerns the gene LCN2 and acute kidney injury.